Request for Nominations for Voting Members for the Genetic Metabolic Diseases Advisory Committee; Amendment of Notice
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is announcing an amendment to the notice of the request for nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee (the Committee) in the Center for Drug Evaluation and Research. This request for nominations was announced in the Federal Register of December 13, 2023. The amendment is being made to reflect a change in the DATES portion of the document. There are no other changes.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 33 (Friday, February 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 33 (Friday, February 16, 2024)]
[Notices]
[Page 12357]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-03302]
[[Page 12357]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0008]
Request for Nominations for Voting Members for the Genetic
Metabolic Diseases Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of the request for nominations for voting
members excluding consumer and industry representatives, to serve on
the Genetic Metabolic Diseases Advisory Committee (the Committee) in
the Center for Drug Evaluation and Research. This request for
nominations was announced in the Federal Register of December 13, 2023.
The amendment is being made to reflect a change in the DATES portion of
the document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Moon Choi, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894, email:
<a href="/cdn-cgi/l/email-protection#15525058515456557371743b7d7d663b727a63"><span class="__cf_email__" data-cfemail="b6f1f3fbf2f7f5f6d0d2d798dedec598d1d9c0">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In the Federal Register of December 13, 2023
(88 FR 86337), FDA announced a request for nominations for voting
members excluding consumer and industry representatives, to serve on
the Genetic Metabolic Diseases Advisory Committee. On page 86337, in
the second column, the DATES portion of the document is changed to read
as follows:
Nominations received on or before March 12, 2024, will be given
first consideration for membership on the Committee. Nominations
received after March 12, 2024, will be considered for nomination to the
Committee as later vacancies occur.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: February 12, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-03302 Filed 2-15-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.